European Journal of Cancer
Volume 44, Issue 11 , Pages 1536-1540 , July 2008

90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial?

  • Hendrik-Tobias Arkenau

      Affiliations

    • Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom
    • H.T.A. and D.O. contributed equally.
    • Corresponding Author InformationCorresponding authors: Tel.: +44 (0) 208 6426011; fax: +44 (0) 208 6427979.
    • ,
  • David Olmos

      Affiliations

    • Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom
    • H.T.A. and D.O. contributed equally.
    • Corresponding Author InformationCorresponding authors: Tel.: +44 (0) 208 6426011; fax: +44 (0) 208 6427979.
    • ,
  • Joo Ern Ang

      Affiliations

    • Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom
    • ,
  • Jorge Barriuso

      Affiliations

    • Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom
    • ,
  • Vasilios Karavasilis

      Affiliations

    • Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom
    • ,
  • Sue Ashley

      Affiliations

    • Department of Computing and Statistics, Royal Marsden Hospital, United Kingdom
    • ,
  • Johann de Bono

      Affiliations

    • Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom
    • ,
  • Ian Judson

      Affiliations

    • Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom
    • ,
  • Stan Kaye

      Affiliations

    • Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom

Received 7 April 2008 ,Accepted 24 April 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Part of this work has been accepted as oral presentation for the 2008 Annual Meeting of American Society of Clinical Oncology.

PII: S0959-8049(08)00330-4

doi: 10.1016/j.ejca.2008.04.017

European Journal of Cancer
Volume 44, Issue 11 , Pages 1536-1540 , July 2008

Article Tools

* Image Usage & Resolution